NasdaqGM - Nasdaq Real Time Price USD

Neurogene Inc. (NGNE)

7.34

-0.52

(-6.68%)

At close: April 8 at 4:00:01 PM EDT

Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome

NEW YORK, April 02, 2025--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced a peer-reviewed publication on its EXACT™ transgene regulation technology. The preclinical studies demonstrate EXACT’s ability to regulate gene therapy expression to a tolerable and therapeutic level, including in preclinical models of Rett syndrome. These data, published in Science Tran

Business Wire 6 days ago

NGNE
-6.68%
Biotech stocks slide as Marks resignation seen being negative for sector

Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is “not good for the biotech industry even beyond vaccines.” Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a “significant negative” for the biopharma and biotech sectors. “NOT GOOD” FOR BIOTECH SECTOR: RBC Capit

TipRanks 7 days ago

GLPG

GLPGF

PTCT
Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates

NEW YORK, March 24, 2025--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced fourth quarter and full year 2024 financial results and highlighted recent corporate updates.

Business Wire 15 days ago

NGNE
-6.68%
Neurogene to Participate in Upcoming Conferences

NEW YORK, February 24, 2025--Neurogene Inc. (NASDAQ: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the following conferences:

Business Wire last month

NGNE
-6.68%
Neurogene Insiders Placed Bullish Bets Worth US$1.46m

Quite a few insiders have dramatically grown their holdings in Neurogene Inc. ( NASDAQ:NGNE ) over the past 12 months...

Simply Wall St. last month

NGNE
-6.68%
Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates

NEW YORK, November 18, 2024--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced third quarter 2024 financial results and highlighted recent corporate updates.

Business Wire 4 months ago

NGNE
-6.68%
How A Side Effect Has Wiped Out 73% Of Neurogene's Value In A Week

Neurogene stock collapsed, again, on Monday after the company scrapped the high dose of its experimental Rett Syndrome treatment.

Investor's Business Daily 4 months ago

NGNE
-6.68%
Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

NEW YORK, November 18, 2024--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced an update on its ongoing Phase 1/2 open-label clinical trial evaluating NGN-401 gene therapy for the treatment of Rett syndrome.

Business Wire 4 months ago

NGNE
-6.68%
Top Biotech Neurogene Crashes 44%, Wiping Out Its Sprint On A $200 Million Deal

Biotech stock Neurogene collapsed Tuesday after a patient experienced a serious side effect in the company's Rett syndrome study.

Investor's Business Daily 4 months ago

NGNE
-6.68%
Neurogene Shares Drop 35% on Rett Syndrome Gene Therapy Trial Data

A serious adverse event occurred in one of two high-dose patients, linked to known risks of AAV gene therapy

GuruFocus.com 4 months ago

NGNE
-6.68%
Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

NEW YORK, November 11, 2024--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced positive interim clinical data in the first four participants in the low-dose cohort of its ongoing Phase 1/2 open-label trial designed to evaluate NGN-401 gene therapy for the treatment of female pediatric patients with Rett syndrome. Low-dose NGN-401 has demonstrated a favorable saf

Business Wire 4 months ago

NGNE
-6.68%
Neurogene Secures $200M for Genetic Therapy Development

Neurogene ( (NGNE) ) has shared an update. Neurogene Inc. has announced a $200 million private placement financing, involving top-tier healthcare funds, to support its innovative genetic therapies for rare neurological diseases. The proceeds are expected to fund the company into the second half of 2027, aiding in the development of its NGN-401 gene therapy for Rett syndrome and other projects. Neurogene aims to maximize the therapeutic impact with its EXACT™ platform, ensuring optimized efficacy

TipRanks 4 months ago

NGNE
-6.68%
Neurogene Announces Oversubscribed $200 Million Private Placement

NEW YORK, November 04, 2024--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it has entered into a securities purchase agreement for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $200 million to Neurogene, before placement agent fees and offering expenses. The oversubscribed PIPE fin

Business Wire 5 months ago

NGNE
-6.68%
Neurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome

NEW YORK, October 21, 2024--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it will host a webcast to present interim efficacy data from the low-dose cohort of its ongoing Phase 1/2 clinical trial of NGN-401 gene therapy for pediatric patients with Rett syndrome on November 11, 2024 at 4:30 p.m. ET. Safety data from the low- and high-dose cohorts will als

Business Wire 5 months ago

NGNE
-6.68%
Neurogene's (NASDAQ:NGNE) Earnings Might Be Weaker Than You Think

Investors appear disappointed with Neurogene Inc.'s ( NASDAQ:NGNE ) recent earnings, despite the decent statutory...

Simply Wall St. 7 months ago

NGNE
-6.68%
Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates

NEW YORK, August 09, 2024--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced second quarter 2024 financial results and highlighted recent corporate updates.

Business Wire 7 months ago

NGNE
-6.68%
Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome

NEW YORK, August 07, 2024--Neurogene Inc. (NASDAQ: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that NGN-401 received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for the treatment of Rett syndrome. The designation was based on preliminary clinical evidence from the ongoing Phase 1/2 clinical trial with NGN-401 that sho

Business Wire 7 months ago

NGNE
-6.68%
Neurogene to Participate in BMO Genetic Medicines Summit

NEW YORK, July 02, 2024--Neurogene Inc. (NASDAQ: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the BMO 2024 Genetic Medicines Summit.

Business Wire 9 months ago

NGNE
-6.68%
Neurogene Announces Addition to Russell 3000® Index

NEW YORK, July 01, 2024--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Neurogene will be added to the Russell 3000® Index, effective at the open of U.S. equity markets today, Monday, July 1, 2024.

Business Wire 9 months ago

NGNE
-6.68%
Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

NEW YORK, June 18, 2024--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the first patient in Cohort 2 received high-dose NGN-401 gene therapy in the Phase 1/2 trial for female pediatric patients with Rett syndrome, and high-dose NGN-401 has been well-tolerated following dosing in May 2024. The Company also provided an update on interim safety data on the

Business Wire 9 months ago

NGNE
-6.68%

Performance Overview

Return	NGNE	S&P 500 (^GSPC)
YTD	-67.89%	-15.28%
1-Year	-82.36%	-4.22%
3-Year	-79.38%	+11.02%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Neurogene Inc. (NGNE)

Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome

Biotech stocks slide as Marks resignation seen being negative for sector

Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates

Neurogene to Participate in Upcoming Conferences

Neurogene Insiders Placed Bullish Bets Worth US$1.46m

Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates

How A Side Effect Has Wiped Out 73% Of Neurogene's Value In A Week

Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

Top Biotech Neurogene Crashes 44%, Wiping Out Its Sprint On A $200 Million Deal

Neurogene Shares Drop 35% on Rett Syndrome Gene Therapy Trial Data

Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

Neurogene Secures $200M for Genetic Therapy Development

Neurogene Announces Oversubscribed $200 Million Private Placement

Neurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome

Neurogene's (NASDAQ:NGNE) Earnings Might Be Weaker Than You Think

Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates

Neurogene Announces RMAT Designation for NGN-401 Investigational Gene Therapy for Rett Syndrome

Neurogene to Participate in BMO Genetic Medicines Summit

Neurogene Announces Addition to Russell 3000® Index

Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

Performance Overview